Safety aspects of incobotulinumtoxinA high-dose therapy

Journal of Neural Transmission

Volumn 122, Issue 2, 2015, Pages 327-333

  Dressler, Dirk ^a   Adib Saberi, Fereshte ^a   Kollewe, Katja ^a   Schrader, Christoph ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Antibody formation; Botulinum toxin; High dose therapy; Safety; Systemic toxicity; Therapeutic use

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ADULT; AGED; BLOOD; DOSE RESPONSE; DYSTONIC DISORDERS; FEMALE; HUMAN; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PROSPECTIVE STUDY; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; AGED; BOTULINUM TOXINS, TYPE A; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSTONIC DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; NEUROMUSCULAR AGENTS; PROSPECTIVE STUDIES; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84929148420     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-014-1252-9     Document Type: Article

References (19)

1. Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME, Turkel CC (2011) OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 51:1358–1573
2. Bocouture: Summary of Product Characteristics (2013). www.medicines.org.uk/emc/medicine/23251
3. ®: Summary of Product Characteristics (2013). www.medicines.org.uk/emc/medicine/112
4. Dressler D (2004a) Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord Suppl 8:S92–S100
5. ®: complete antibody-induced therapy failure in hemifacial spasm. J Neurol 251:360
6. Dressler D (2005) Botulism caused by consumption of smoked salmon. Nervenarzt 76:763–766
7. Dressler D (2012) Clinical applications of botulinum toxin. Curr Opin Microbiol 15:325–336
8. Dressler D, Benecke R (2003) Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 49:34–38
9. Dressler D, Dirnberger G (2000) Botulinum toxin therapy: risk factors for therapy failure. Mov Disord 15(suppl 2):51
10. Dressler D, Wohlfahrt K, Meyer-Rogge E, Wiest L, Bigalke H (2011) Antibody-induced botulinum toxin therapy failure in dermal indications. Dermatol Surg 36(Suppl 4):2182–2187
11. Girlanda P, Vita G, Nicolosi C, Milone S, Messina (1992) Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry 55:844–845
12. Göschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H (1997) Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies–therapeutic consequences. Exp Neurol 147:96–102
13. Lange DJ, Brin MF, Warner CL, Fahn S, Lovelace R (1987) Distant effects of local injection of botulinum toxin. Muscle Nerve 10:552–555
14. Olney RK, Aminoff MJ, Gelb DJ, Lowenstein DH (1988) Neuromuscular effects distant from the site of botulinum neurotoxin injection. Neurology 38:1780–1783
15. Rosow DE, Parikh P, Vivero RJ, Casiano RR, Lundy DS (2013) Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia. Otolaryngol Head Neck Surg 148:1003–1006
16. Scott AB (1980) Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus 17:21–25
17. Truong D, Dressler D, Hallett M (2009) Manual of botulinum toxin therapy. Cambridge University Press, Cambridge
18. Vistabel: Summary of Product Characteristics (2013). www.medicines.org.uk/emc/medicine/17580
19. ®: Summary of Product Characteristics (2013). www.medicines.org.uk/emc/medicine/20666